Start-Up Nation Finder

45 companies were selected

Add smartlist note (optional)

Smartlist name*

Smartlist must have a valid name.

Description (optional)

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

The invitation to claim the profile was originally sent to

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

Name*

Work Email* (please provide your email in the organization)

Position*

Notes

I agree to receive Informational Emails from Start-Up Nation Finder as defined in the Privacy Policy and Terms of Use

Already have an account?

Search Was Saved

Home > Companies > EndoSpan

Claimed by owner • Last Update 14.12.2021 • Suggest Edits • Claim Profile

Claimed by owner

EndoSpan

Stent Graft Systems for Aneurysms and Dissections

EndoSpan

www.businesswire.com • Nov 1, 2021

Endospan Reports Landmark Publication on the Initial Experience With the NEXUS™ Aortic Arch Stent Graft System

www.businesswire.com • Jan 12, 2021

Endospan Enrolls First Patient in the TRIOMPHE IDE Study

www.businesswire.com • Aug 17, 2020

Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System

www.businesswire.com • Apr 20, 2020

FDA Grants NEXUS™ Aortic Arch Stent Graft System Breakthrough Designation

www.calcalistech.com • Sep 15, 2019

CyroLife Signs Option to Acquire EndoSpan for up to $450 Million

www.businesswire.com • Sep 12, 2019

Endospan Enters Into Strategic Distribution Agreement With CryoLife

vascularnews.com • Mar 20, 2019

Endospan secures CE mark for Nexus stent graft system - Vascular News

vascularnews.com • Feb 7, 2019

CE mark approval for Nexus aortic arch stent graft expected in Q1 2019 - Vascular News

www.businesswire.com • May 14, 2018

Endospan Elects Jeff Elkins as a Director

www.tctmd.com • Mar 22, 2018

Endospan Receives CE Mark for HORIZON™ EVAR System Based on Robust Clinical and Pivotal Data to Treat Abdominal Aortic Aneurysm (AAA)

www.businesswire.com • Mar 12, 2018

Endospan Appoints Kevin J. Mayberry as CEO

www.geektime.com • Oct 23, 2015

http://www.geektime.com/2015/10/22/chinese-pharma-company-pumps-10-million-in-israeli-heart-tech/

Endospan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic. Endospan helps make the treatment of aneurysms, dissections, and aortic lesions simpler and less invasive, making it a suitable choice for patients with limited treatment options.

Endospan's HORIZON system can be used in a single-sided approach, generally shortening and simplifying EVAR procedures. It is especially useful for patients for whom a two-sided approach is physically impossible because of occlusions, natural anatomical contraindications, or other pathologies arising from prior surgical intervention.

The company's NEXUS is an aortic stent graft system whose modular approach offers a minimally invasive endovascular solution for patients diagnosed with an aneurysm in the ascending aorta or the aortic arch.

In March 2019, Endospan announced that it received the CE Mark for its Nexus stent graft system to be used for branched endovascular repair in the aortic arch. In April 2020, the Nexus aortic arch stent graft system received FDA breakthrough device designation.